摘要
目的观察沙美特罗替卡松(舒利迭)联合苏黄止咳胶囊对咳嗽变异性哮喘(CVA)的治疗效果。方法将50例临床诊断为CVA的患者随机分为两组。A:23例,舒利迭(50/250ug)吸入,每日2次。B:27例,舒利迭(50/250μg)吸入,每日2次,同时口服苏黄止咳胶囊3粒/次,每日3次。2周后比较两组患者的咳嗽症状积分和咳嗽敏感性,4周后比较两周患者的复发率。结果 2周后,与A组比较,B组的咳嗽症状积分(P>0.05)无显著差异,而咳嗽敏感性(P<0.05)降低,4周后,B组总复发率较A组下降。结论舒利迭联合苏黄止咳胶囊治疗能降低CVA患者的咳嗽敏感性,减少复发率。
Objective To investigate the effect of salmeterol/fluticasone and Su Huang cough relieve capsule in the treatment of patients with CVA. Methods 50 patients with CVA were randomly divided into two groups. The group A （ n = 23 ） were given 50 txg of salmeterol and 250 t^g of fluticasone twice a day. The group B （ n = 27 ） were given 3 pills of Su Huang cough relieve capsule once and 3 times a day on the basis of salmeterol/fluticasone （50/250 p^g）. The cough symptom score and cough reflex sensitivity were compared after 2 weeks and the relapse rate was compared after 4 weeks. Results After 2 weeks, the difference of cough symptom score between the two groups had no statistical significance （P 〉 0. 05 ）, but there was significant difference in cough reflex sensitivity between the two groups （ P 〈 0.05 ）. The relapse rate of the group B was lower than that of the group A 4 weeks after. Conclusion The combination therapy of salmeterol/flutleasone and Su Huang cough relieve capsule can reduce the cough reflex sensitivity and relapse rate of patients with CVA.
出处
《临床肺科杂志》
2013年第2期257-258,共2页
Journal of Clinical Pulmonary Medicine
关键词
沙美特罗替卡松
苏黄止咳胶囊
咳嗽变异性哮喘
salmeterol/fluticasone
Su Huang cough relieve capsule
cough variant asthma （CVA）
